Managing Complications of Surgical Implants

Evolve Image
Media formats available:
Details
Presenters
  • Overview

    In this video about complications of surgical implants for the treatment of retinal disease, Veeral Sheth, MD, MBA, FASRS, FACS, and Margaret A. Chang, MD, MS, share strategies for early intervention and steps for managing long-term adverse events.

  • Target Audience

    This certified CME activity is designed for retina specialists who care for patients with retinal diseases.

  • Grantor Statement

    This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Formulate an action plan for managing complications associated with surgical implants
  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education


    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Faculty

    Veeral Sheth, MD, MBA, FASRS, FACS (Chair)
    Director of Clinical Research
    University Retina and Macula Associates
    Board Certified Ophthalmologist and Retinal Surgeon
    Clinical Assistant Professor
    University of Illinois at Chicago
    Chicago, IL

    Margaret A. Chang, MD, MS
    Retinal Consultants Medical Group
    Sacramento, CA

  • Disclosure of Relevant Financial Relationships

    DISCLOSURE POLICY

    In accordance with the ACCME Standards for Integrity and Independence , it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.

    The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.

    Veeral S. Sheth, MD, MBA, FASRS, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alkeus, Apellis, Boehringer Ingelheim, EyePoint Pharmaceuticals, Genentech, Iveric Bio, Janssen, Kriya Therapeutics, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Ollin Biosciences, Opthea, Regeneron, RevOpsis, Unity, and Vial. Grant/Research Support: 4DMT, AbbVie, Adverum Biotechnologies, Alimera Sciences, Ashvattha Therapeutics, Astellas, Aviceda, Chengdu Kanghong, Eluminex Biosciences, Eyebiotech, Eyepoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Ionis, Iveric Bio, Janssen Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Oculus, Ocugen, OcuTerra, Olix, Opthea, Outlook, Oxular, Oxurion, Perfuse Therapeutics, Recens Medical, Regeneron, Regenxbio, Rezolute, Roche, SalutarisMD, SamChungDang, Santen, Smilebiotek, Unity Biotechnology, and Vanotech. Speaker's Bureau: Genentech and Iveric Bio.

    Margaret A. Chang, MD MS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Regenxbio, Astellas, Boehringer Ingelheim, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Genentech, Ocular Therapeutix, Oculis, and Opthea. Grant/Research Support: Alexion, EyeBio, Kodiak Sciences, Mylan, NGM Biopharmaceuticals, Novartis, OcuTerra, and Outlook Therapeutics. Speaker's Bureau: Genentech.

    The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying Eye Health Academy…
but how about a more personalized experience?

Register for free